Supramolecular assembly of polycation/mRNA nanoparticles and in vivo monocyte programming.
mRNA delivery
monocyte transfection
nanoparticle assembly
poly(beta-amino ester)
vehicle size-mediated passive targeting
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
ppublish
Résumé
Size-dependent phagocytosis is a well-characterized phenomenon in monocytes and macrophages. However, this size effect for preferential gene delivery to these important cell targets has not been fully exploited because commonly adopted stabilization methods for electrostatically complexed nucleic acid nanoparticles, such as PEGylation and charge repulsion, typically arrest the vehicle size below 200 nm. Here, we bridge the technical gap in scalable synthesis of larger submicron gene delivery vehicles by electrostatic self-assembly of charged nanoparticles, facilitated by a polymer structurally designed to modulate internanoparticle Coulombic and van der Waals forces. Specifically, our strategy permits controlled assembly of small poly(β-amino ester)/messenger ribonucleic acid (mRNA) nanoparticles into particles with a size that is kinetically tunable between 200 and 1,000 nm with high colloidal stability in physiological media. We found that assembled particles with an average size of 400 nm safely and most efficiently transfect monocytes following intravenous administration and mediate their differentiation into macrophages in the periphery. When a CpG adjuvant is co-loaded into the particles with an antigen mRNA, the monocytes differentiate into inflammatory dendritic cells and prime adaptive anticancer immunity in the tumor-draining lymph node. This platform technology offers a unique ligand-independent, particle-size-mediated strategy for preferential mRNA delivery and enables therapeutic paradigms
Identifiants
pubmed: 39172792
doi: 10.1073/pnas.2400194121
doi:
Substances chimiques
RNA, Messenger
0
Polyelectrolytes
0
polycations
0
Polyamines
0
poly(beta-amino ester)
0
Polymers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2400194121Subventions
Organisme : HHS | NIH | National Cancer Institute (NCI)
ID : R01CA281143
Organisme : HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : U01AI155313
Organisme : HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : R21AI160738
Organisme : HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)
ID : P41EB028239
Organisme : HHS | NIH | National Cancer Institute (NCI)
ID : R37CA246699
Déclaration de conflit d'intérêts
Competing interests statement:S.K.R., J.J.G. and H.-Q.M. are cofounders of Wyverna Therapeutics Inc. Y.H. was a consultant for Wyverna Therapeutics Inc. Y.H., S.Y.T., L.C., J.J.G. and H.-Q.M. are inventors of a patent application covering the nanoparticle assembly technology described here; S.Y.T., D.R.W., Y.R. and J.J.G. are inventors of a patent application covering the PBAE structures described here.Both patents were filed through and are managed by Johns Hopkins Technology Ventures. The other authors declare no conflict of interest.